Weight Loss and GLP-1 Side Effects


Understanding GLP-1 Medications
GLP-1 receptor agonists like Ozempic, Mounjaro, and Wegovy are changing weight loss treatment. They mimic hormones that reduce appetite and keep you feeling full but come with potential side effects.

Nausea and Digestive Issues
Nausea, vomiting, and diarrhea are common side effects, especially when starting treatment. These symptoms often improve over time as your body adjusts to the medication.

Taste Changes and Food Aversions
Many people report that their sense of taste chances, or they no longer enjoy favorite foods. Sweet and fatty foods may become particularly unappetizing while on GLP-1 medications.

Injection Site Reactions
Some patients experience redness, itching, or swelling at injection sites. Injecting yourself in different spots each time and using the right technique can help minimize these reactions.

Pancreas Problems
In rare cases, GLP-1 medications may cause pancreatitis, or an inflamed pancreas. Seek immediate medical help if you have severe abdominal pain that radiates to your back.

Muscle Loss
You can lose both fat and muscle while on these medications. Make sure you're getting enough protein and do regular strength training to preserve muscle mass.

Gallbladder Complications
Rapid weight loss increases the risk of gallstones or an inflamed gallbladder. Let your doctor know about any upper abdominal pain.

Hair Thinning
Some people experience temporary hair thinning due to hormonal changes and reduced nutrient intake. Make sure you're getting enough protein and vitamins.

Mood Changes
Some people have mood changes, including depression and anxiety, while on GLP-1s. Let your healthcare provider know about changes in your mental wellbeing.

Thyroid Concerns
Animal studies showed an increased risk of thyroid tumors with some GLP-1 medications, but it's not yet known if it can cause thyroid cancer in people.

When to Seek Help
Get medical help immediately for severe abdominal pain, persistent vomiting, or signs of allergic reaction. Tell your doctor if side effects significantly impact your quality of life.
PHOTO CREDENTIALS
Slide 1 - Moment / Getty Images
Slide 2 - Hryshchyshen Serhii / Shutterstock
Slide 3 - iStock / Getty Images
Slide 4 - Troyan / Shutterstock
Slide 5 - iStock / Getty Images
Slide 6 - Prostock-studio / Shutterstock
Slide 7 - Peakstock / Shutterstock
Slide 8 - Oporty786 / Shutterstock
Slide 9 - THICHA SATAPITANON / Shutterstock
Slide 10 - PeopleImages.com - Yuri A / Shutterstock
Slide 11 - Phynart Studio / Getty Images
SOURCES
Eli Lilly and Company: “Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes.”
FDA: “FDA Approves New Medication for Chronic Weight Management,” “Mounjaro (tirzepatide) Highlights of Prescribing Information,” “Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity,” “MOUNJAROTM (tirzepatide) Injection, for subcutaneous use.”
Phelps Health: “Understanding Mounjaro: A Guide for Type 2 Diabetes Patients.”
University of Colorado Health: “What is Mounjaro? And does it work better for weight loss than Ozempic and Wegovy?”
Cleveland Clinic: “How Mounjaro Is Helping People With Obesity Lose Weight,” “Gastroparesis.”
The New England Journal of Medicine: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.”
HCP Live: “Management of Nausea Resulting from GLP1 Agonists for T2DM.”
Harvard Medical School: “GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more.”
Journal of Clinical Medicine: “Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus.”
Houston Methodist: “Home Remedies for Heartburn: 8 Ways to Get Rid of Acid Reflux.”
International Journal of Clinical Pharmacology: “Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.”
Mayo Clinic: “Tirzepatide (subcutaneous route),” “Pancreatitis.”
Frontiers in Endocrinology: “Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.”
Medscape: “Tirzepatide (Rx).”
University of British Columbia: “Weight-loss drugs linked to stomach paralysis, other serious gastrointestinal conditions.”
American Diabetes Association: “Tirzepatide Slowed Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes with Increased Cardiovascular Risk.”
Clinical Kidney Journal: “Tirzepatide and prevention of chronic kidney disease.”
Johns Hopkins Medicine: “Diabetes and Your Eyes: What You Need to Know,” “Gallstones.”
American Academy of Ophthalmology: “6 Surprising Facts About Diabetes and Your Eyes.”
NEJM Journal Watch: “Gastrointestinal Adverse Events in Patients Taking GLP-1 Agonists for Weight Loss.”
Clinical Pharmacology and Therapeutics: “Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients with Type 2 Diabetes.”
National Library of Medicine: “Intestinal obstruction and Ileus.”
Asthma and Allergy Foundation of America: “Anaphylaxis (Severe Allergic Reaction).”
FDA: “Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss,” “Ozempic: Highlights of prescribing information,” “Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity,” “MPM: V-9. Fruits and Fruit Products (V-51 to V-78).”
Mayo Clinic: “How does semaglutide work?” “Constipation,” “Pancreatitis,” “Gastroparesis,” “Heartburn,” “Semaglutide: Subcutaneous Route,” “Belching, gas and bloating: Tips for reducing them.”
The New England Journal of Medicine: “Once-Weekly Semaglutide in Adults with Overweight or Obesity.”
Ozempic: “Possible side effects of Ozempic.”
UCLA Health: “Semaglutide for weight loss – what you need to know.”
Diabetes, Obesity and Metabolism: “Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.”
Molecules: “Role of Sulfur Compounds in Vegetable and Mushroom Aroma.”
Journal of Food Composition and Analysis: “Sulfur content in foods consumed in an Italian population and impact of diet quality on sulfur intake.”
St. Luke’s Health System Kansas City: “Understanding Post-Injection Inflammation.”
Novo Nordisk: “Ozempic semaglutide injection: Highlights of prescribing information.”
Houston Methodist: “Home Remedies for Heartburn: 8 Ways to Get Rid of Acid Reflux.”
Antioxidants and Redox Signaling: “Hydrogen Sulfide Signaling in the Gastrointestinal Tract.”
Cleveland Clinic: “Gastroparesis.”
University of British Columbia: “Weight-loss drugs linked to stomach paralysis, other serious gastrointestinal conditions.”
Ozempic: “Important safety information.”
American Academy of Allergy, Asthma, and Immunology: “Angioedema after semaglutide.”
Novomedlink: “Safety profile for once-weekly Ozempic (semaglutide) injection.”
Baton Rouge General: “Side Effects of Ozempic and Similar Drugs You Should Be Concerned About.”
Diatribe: “FDA Updates Ozempic Label With Warning for Intestinal Blockages.”
Frontiers in Endocrinology: “Safety of Semaglutide updated.”
Nature: “Ozempic keeps wowing: trial data show benefits for kidney disease,” “Does Ozempic boost fertility? What the science says.”
Cedars-Sinai: “Good Morning America: Is Ozempic Safe to Take During Pregnancy or While Trying to Conceive? Experts Weigh In.”
Menopause: “Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use.”
National Institutes of Health: “People taking semaglutide had lower risk of suicidal thoughts.”
Asthma and Allergy Foundation of America: “Anaphylaxis (Severe Allergic Reaction).”
Harvard Medical School: “GLP-1 diabetes and weight-loss drug side effects: ‘Ozempic face’ and more.”
National Health Service (U.K.): “Feeling Sick (Nausea).”
Carolynn Francavilla Brown, MD, obesity specialist; diplomate, Board of Obesity Medicine; owner, Green Mountain Partners for Health and Colorado Weight Care, Denver.
International Archives of Otolaryngology: "The Impact of Acute Loss of Weight on Eustachian Tube Function."
Endocrine 2024, annual meeting of the Endocrine Society, Boston, June 1, 2024.
Mojca Jensterle Sever, PhD, University Medical Center, Ljubljana, Slovenia.
Megan Melo, MD, family and obesity medicine doctor, Phinney Primary Care and Wellness, Seattle.
Sofia Spieler, Boston.
Diabetes & Metabolism Journal: “Consequences of Obesity on the Sense of Taste: Taste Buds as Treatment Targets?”
Nutrition Reviews: “Temporal patterns in taste sensitivity.”
Farhad Mehrtash, MPH, co-author, GLP-1 weight loss medication guidelines, Harvard T.H. Chan School of Public Health.
JoAnn E. Manson, MD, professor of medicine, Harvard Medical School.
Samuel Klein, MD, professor of medicine and nutritional science, Washington University, St. Louis.
Jody Dushay, MD, assistant professor of medicine, Harvard Medical School.
JAMA Internal Medicine: "Integrating Diet and Physical Activity When Prescribing GLP-1s – Lifestyle Factors Remain Crucial," "I Am Taking a GLP-1 Weight-Loss Medication – What Should I Know?"
CDC: "Adult Activity: An Overview."
The National Weight Control Registry: "NWCR Facts."
Brian Abittan, MD, director of Skin and Hair Rejuvenation and director of Hair Transplantation, Kimberly and Eric J. Waldman Department of Dermatology, Mount Sinai, New York City.
Mayo Clinic: “Hair loss.”
American Academy of Dermatology: “Hair Loss Types: Alopecia Areata Signs and Symptoms,” “Hair Loss: Who Gets and Causes,” “Hair Loss: Signs and Symptoms,” “Hair Loss: Tips for Managing.”
NYU Langone Health: “Types of Hair Loss,” “Medication for Hair Loss.”
Cleveland Clinic: “Folliculitis Decalvans,” “Hair Loss,” “Hair Loss Treatments, “Scalp Micropigmentation,” “Does Creatine Cause Hair Loss?” “When to Worry about Hair Loss.”
Michael Pan, MD, dermatologist who specializes in hair loss, Cedars Sinai, Los Angeles.
Harvard Nutrition Source: “Biotin - Vitamin B7.”
Medscape: “Does Ozempic Cause Hair Loss?”
Medical News Today: “Ozempic, Wegovy Under Investigation for Side Effects of Suicide Ideation, Hair Loss.”
American Society for Dermatologic Surgery.
American Academy of Family Physicians.
National Institute of Diabetes and Digestive and Kidney Disease: "Prescription Medications to Treat Overweight & Obesity."
FDA: "FDA Drug Safety Communication: Completed Safety Review of Xenical/Alli (orlistat) and Severe Liver Injury," "Medications Target Long-Term Weight Control," "FDA Approves New Medication for Chronic Weight Management, "Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss."
MedlinePlus: "Phentermine."
The American Journal of Managed Care: "FDA Approves Diabetes Drug Tirzepatide for Chronic Weight Management."
novo-pi.com: "Saxenda."
static.contrave.com: "Contrave."
CDC: "Adult BMI Calculator."
Yale Medicine: "Do Anti-Obesity Medications Really Work?"
GoodRX Health: "Is Ozempic Covered By Insurance?
Wegovy.com.
Ozempic.com.
Diabetes, Obesity, and Metabolism: "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension."
UC Davis Health: "Ozempic for weight loss: Does it work, and what do experts recommend?"
Harvard Health Publishing: "GLP-1 diabetes and weight-loss drug side effects: 'Ozempic face' and more."
Medscape: "Exenatide injectable solution (Rx)."
Trulicity.com.
Frontiers in Endocrinology: "Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity."
News release, Eli Lilly.
Journal of the American Medical Association: "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial."
Diabetes, Obesity & Metabolism: "Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison."
Xenical.com.
Qsymia.com.
Zepbound.lilly.com.
Mounjaro.lilly.com.
MyPlenity.com.
Clinical Diabetes: "Plenity (Oral Superabsorbent Hydrogel)."
International Journal of Obesity: "What is the pipeline for future medications for obesity?"
Obesity Medicine Association: "Does Insurance Cover Weight Loss Medication?" "Top Weight Loss Medications."
JAMA Network Open: "Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial."
UC Health: "Wegovy vs. Ozempic: The truth about new ‘weight-loss’ drugs."
New York-Presbyterian Health Matters: "Understanding Ozempic, Wegovy, and Weight Loss Medications."
Columbia University Irving Medical Center: "Popularity of Weight Loss Drugs Soars, but Weight Stigma Persists."